Key points are not available for this paper at this time.
Comment on Offidani et al, page 21591, and comment on Mateos et al, page 21652 Complete response has been a primary end point in many cancer therapy trials—including the two reported in this issue for elderly patients with multiple myeloma—but does not per se translate into survival
Barlogie et al. (Wed,) studied this question.